Drugs / BAY 3547926
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06764316 | Feb 2025 → Jul 2029 expected | hepatocellular carcinoma | Bayer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 3547926 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06764316 ↗ |
| Modality | Protein / enzyme biologic | “antibody conjugate with actinium-225 label” NCT06764316 ↗ |